key: cord-0285883-rujrd7f9 authors: Díez, José María; Romero, Carolina; Gajardo, Rodrigo title: Effective presence of antibodies against common human coronavirus in IgG immunoglobulin medicinal products date: 2021-07-23 journal: bioRxiv DOI: 10.1101/2021.07.23.453571 sha: 2f05d3084702caa7badd5fa315428bdd7a7a2a14 doc_id: 285883 cord_uid: rujrd7f9 Introduction In this series of studies, immunoglobulin products (IgG) formulated for different routes of administration (IV, IM, SC) and prepared from geographically diverse plasma pools were tested for activity against common human coronaviruses (HCoV). IgG products from plasma obtained from Germany, Czech Republic, Slovak Republic, USA and Spain were tested for antibodies to four common HCoV: 229E, OC43, NL63 and HKU1. Since these products are manufactured from pooled plasma from thousands of donors, the antibodies therein are a representation of the HCoV exposure of the population at large. Methods IgG products of different concentrations manufactured from geographically diverse plasma pools were tested for antibodies to four common HCoV by ELISA. In addition, neutralization assays were conducted using HCoV-229E expressed in MRC5 cells. Complete concentration-neutralization curves were obtained to calculate potencies. Results The ELISA assays showed that when expressed as specific activity (anti-HCoV activity/mg IgG) similar activity against the four common HCoV was seen across the IgG products regardless of concentration or geographic origin. Highest anti-HCoV activity was seen against HCoV-229E, followed by HCoV-OC43 and then HCoV-NL63 and HCoV-HKU1. The neutralization assays showed similar potency for two preparations of IgG prepared by different processes. Conclusions These studies are the first demonstration of antibodies to common HCoV in IgG products. The level of activity was similar regardless of the geographic origin of the plasma pool. These antibodies demonstrated neutralization activity against HCoV-229E in MRC5 cells. These results may explain the cross-reactivity seen with pre-pandemic IgG products and SARS-CoV-2 and contribute to the variability in disease course in different patients. It is important to note that coronaviruses in the same subgroup, particularly 71 betacoronavirus such as HCoV-OC43, HCoV-HKU1, SARS-CoV, SARS-CoV-2 and 72 MERS-CoV, show some interactivity in antigenic responses. Cross reactivity between 73 SARS-CoV and MERS-CoV with other human betacoronaviruses has become 74 apparent (12-14). The fact that the new betacoronavirus SARS-CoV-2 is directly 75 related to SARS-CoV (they share more than 90% sequence homology) (15) suggests 76 that antigenic interactivity between them is possible, at least for some proteins. In 77 addition, recently, reactions to SARS-CoV-2 in pre-pandemic immunoglobulin solutions 78 have been observed (16). Furthermore, these solutions have some neutralizing 79 capacity (17). 80 In this study, immunoglobulin (IgG) solutions for intravenous, intramuscular and 81 subcutaneous administration were analyzed for the presence of antibodies to common 82 HCoV. This project was designed to detect, for the first time, common HCoV antibodies The IgG titers (anti-coronavirus activity/mL) for the immunoglobulin products are 120 shown in Figure 1 . When expressed in this manner, the lower concentration of 121 immunoglobulins (5%) showed less activity than the higher concentrations (10-20%). 122 For products of similar concentration, IgG activity was similar regardless of the 123 geographic origin of the plasma pool. Overall, the highest activity was seen against the 124 HCoV-229E and HCoV-OC43 strains. 125 The similarity becomes clearer when the data were expressed as specific 126 activity (anti-coronavirus activity/mg IgG: Figure 2 ). These data show that anti-127 coronavirus activity was consistent across the products regardless of the total IgG 128 concentration and the origin of the plasma pool. Activity was highest against the HCoV-129 229E followed by HCoV-OC43. Similar lower level activity was seen against HCoV-130 NL63, and HCoV-HKU1. 131 When the data from all the products was combined, the mean specific activity Co-infection with other respiratory viruses was also a common finding (9, 18, 20) . 173 A global, systematic review and meta-analysis of data from 1995-2020 in 174 pediatric and adult patients showed that OC43 was the most prevalent common HCoV 175 (estimated prevalence 2.40%) followed by NL63 (1.60%), HKU1 (1.04%) and 229E 176 (0.97%). These data were collected almost exclusively in developed countries (97%) 177 (1). 178 Given the above studies showing differences in the prevalence of common CoV and MERS-CoV and other human betacoronaviruses has been reported (12-14) . 208 The fact that the recently identified betacoronavirus, SARS-CoV-2, is closely related to 209 SARS-CoV (> 90% sequence homology) (15) suggests that antigenic interactivity 210 between them is possible, at least for some proteins. IgG/mL-neutralization %) were generated for virus neutralization and IC50 values were 267 calculated. The IC50 for Flebogamma ® -DIF was 0.503 mg IgG/mL which was very 268 similar to the IC50 for Gamunex ® -C (0.553 mg IgG/mL). 269 270 Systematically mapping clinical features 272 of infections with classical endemic human coronaviruses Global patterns in 274 coronavirus diversity A new virus isolated from the human respiratory tract Identification of a new human coronavirus Recovery in tracheal organ 280 cultures of novel viruses from patients with respiratory disease Characterization and 283 complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with 284 pneumonia Genetic Recombination, 286 and Pathogenesis of Coronaviruses Human 288 coronavirus circulation in the United States Epidemiology and clinical 290 presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 291 years using a novel multiplex real-time PCR method Antibody Response 293 against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients. 294 mSphere Distinct antibody 296 repertoires against endemic human coronaviruses in children and adults Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS 299 Cross-reactive antibodies in 301 convalescent SARS patients' sera against the emerging novel human coronavirus by both immunofluorescent and neutralizing antibody tests Antigenic cross-reactivity 304 between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 305 229E and OC43 Profiling Early Humoral Response 307 to Diagnose Novel Coronavirus Disease (COVID-19) Currently available intravenous immunoglobulin 309 contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 310 antigens Cross-312 neutralization activity against SARS-CoV-2 is present in currently available intravenous 313 immunoglobulins High incidence but 315 low burden of coronaviruses and preferential associations between respiratory viruses Increased Detection of Viruses 321 Children with Respiratory Tract Infection Using PCR Etiology and clinical characteristics 324 of SARS-CoV-2 and other human coronaviruses among children in Zhejiang Province Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not 328 associated with protection Does common cold coronavirus infection protect against 330 severe SARS-CoV-2 disease?